RegentAtlantic Capital’s 9 Meters Biopharma NMTR Stock Holding History

RegentAtlantic Capital’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,066	Closed	-$11K	–	710
2022 Q2	$11K	Hold	2,066	–	–	﹤0.01%	674
2022 Q1	$25K	Hold	2,066	–	–	﹤0.01%	685
2021 Q4	$40K	Hold	2,066	–	–	﹤0.01%	681
2021 Q3	$54K	Hold	2,066	–	–	﹤0.01%	651
2021 Q2	$45K	Hold	2,066	–	–	﹤0.01%	632
2021 Q1	$48K	Hold	2,066	–	–	﹤0.01%	543
2020 Q4	$35K	Hold	2,066	–	–	﹤0.01%	495
2020 Q3	$34K	Buy	2,066 +1,466	+244%	+$17.8K	﹤0.01%	485
2020 Q2	$7K	Buy	+600	New	+$6.76K	﹤0.01%	475

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

RegentAtlantic Capital's NMTR Position: Q3 2022 in Review

RegentAtlantic Capital sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 2,066 shares — an estimated $11K sold.

RegentAtlantic Capital first reported a position in NMTR in Q2 2020 and held it in 9 quarters. The position peaked at $54K in Q3 2021. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

RegentAtlantic Capital reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
RegentAtlantic Capital sold 2,066 9 Meters Biopharma shares in Q3 2022, an estimated $11K.
RegentAtlantic Capital first reported a position in 9 Meters Biopharma in Q2 2020 and held it in 9 quarters.
RegentAtlantic Capital's 9 Meters Biopharma position peaked at $54K in Q3 2021.
74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.